Claim and evidence Close ×
Generate Biomedicines' IPO prospectus (26 February 2026) states that it entered a collaboration and license agreement with Amgen in December 2021, receiving a $50.0 million upfront payment in January 2022, and one with Novartis in September 2024, receiving a $50.0 million upfront payment in October 2024. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Provision Statement · provision ID co-generate-amgen-novartis-2026 Date 2026-02-26 · publication Records dated 2026 → Scope and limits The issuer's statement in an offering document of agreements entered and payments received; milestone eligibility is not recorded. The prospectus also states equity investments by both partners, not recorded here.
The evidence 02 primary source Supports the claim
Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock ↗ Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “In December 2021, we entered into a collaboration and license agreement with Amgen, as amended (as amended from time to time, the “Amgen Collaboration Agreement”), and, in connection therewith, we received a non-refundable upfront payment of $50.0 million in January 2022” Location in source Risk factors, paragraph beginning "To date, we have financed our operations" (prospectus p. 19)
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Generate Biomedicines, Inc. (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (41 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Supports the claim
Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock ↗ Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “In September 2024, we entered into a collaboration and license agreement with Novartis (the “Novartis Collaboration Agreement”), and, in connection therewith, we received a non-refundable upfront payment of $50.0 million in October 2024” Location in source Risk factors, paragraph beginning "To date, we have financed our operations" (prospectus p. 19)
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Generate Biomedicines, Inc. (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (33 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.
Date. Dated by the prospectus; the agreement months and receipt months are the company's statements within it.
Record ID aib-co-generate-amgen-novartis-2026